Research, regulatory trends suggest ESAs should play declining role in patient care.
| Autor: | Boyle, Simone N., Bennett, Charles L. |
|---|---|
| Zdroj: | Oncology News International; May2008, Vol. 17 Issue 5, p16-16, 1p |
| Abstrakt: | The article examines the validity of claims that erythropoietin-stimulating agents (ESA) increase mortality risk among cancer patients. According to the authors, the two agents that are in the center of the debate are Procrit and Aranesp. The authors analyze various studies to present the pros and cons of ESA. |
| Databáze: | Supplemental Index |
| Externí odkaz: |
|